Drug Makers Could Hike Prices Before Inflationary Rebates Kick In

By Rachel Cohrs
August 12, 2019 at 3:50 PM
The controversial inflationary rebate policy in the Senate Finance Committee’s drug-pricing package could incentivize drug makers to raise prices before the bill would take effect in 2022, sources say. Others disagree and say that drug makers could make up revenue in different ways. The inflationary rebates as outlined in the plan passed by the Finance Committee would begin in 2022 and would be indexed to July 2019 list prices trended forward by inflation. Starting Jan. 1, 2022, drug makers would...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.